Ottobock Invests in Blue Arbor Technologies for Advanced Prosthesis Control

Ottobock SE & Co. KGaA has announced a strategic investment of USD 5 million in Blue Arbor Technologies, Inc., as part of a Series A financing. This move aims to enhance the development of the RESTORE implant technology, which promises more intuitive prosthesis control. This novel system, developed by Blue Arbor, involves a neuromuscular interface with electrodes implanted into muscles connected to nerves, enabling natural prosthesis movement.

The RESTORE system allows independent and simultaneous movement of fingers, wrists, and elbows, improving dexterity. A successful first test was conducted at the Medical University of Vienna, where a patient could use the system quickly with an Ottobock prosthesis. The FDA has granted the system a Breakthrough Device designation. Ottobock's investment solidifies its position as a major investor, offering a promising future for prosthesis technology.